reducing risk in residual breast cancer
Published 5 years ago • 4.4K plays • Length 2:25Download video MP4
Download video MP3
Similar videos
-
2:00
ribociclib in early breast cancer | nejm
-
1:57
reducing the risk of thromboembolism in cancer
-
47:45
reduce the risk of recurrence with nerlynx | webinar on therapeutic decision-making
-
7:11
case 1: adjuvant therapy for residual disease in her2 breast cancer
-
1:16
tackling residual disease in breast cancer
-
47:29
optimizing therapy in her2 disease with dr. reshma mahtani
-
1:00
utilizing neoadjuvant immunotherapies in patients with er , her2- primary breast cancer
-
1:54
reducing hospital stays in infective endocarditis
-
52:08
emerging strategies in breast cancer care before, during and after surgery
-
52:21
new & supporting data for optimizing therapy in her2 breast cancer | dr. irene and dr. vogel
-
2:46
ameera-3: amcenestrant does not improve pfs in er /her2- breast cancer
-
1:59
effectiveness of icis in the neoadjuvant and post-neoadjuvant breast cancer setting
-
39:22
optimizing therapy in her2 disease with dr. kevin kalinsky
-
1:49
early breast cancer: do we need chemotherapy in low genomic/high clinical risk (er /her2-)?
-
2:05
treatment advances in tnbc
-
58:22
adjuvant cdk4 and 6 inhibition to prevent recurrences in high-risk hr /her2- early breast cancer
-
49:25
optimizing therapy in her2 disease with dr. hope s. rugo
-
1:56
optimizing adjuvant treatment in hr /her2- early breast cancer